To review our experience in managing infants with hypoplastic left heart syndrome (HLHS) and to establish a consistent approach in counseling families based on our experience and on review of medical literature.
Hypoplastic left heart syndrome (HLHS) is the most common cause of death from congenital heart disease in the first week of life, with an average life expectancy of 5 days. 1 This malformation represents 7% to 9% of congenital heart disease, with an incidence of 0.26/1000 live births. 2 Until the 1980s, HLHS was considered to be a fatal condition for which no curative therapy existed.
Heart transplantation (HT) and staged palliative surgery are now available as therapeutic options for HLHS. In 1980, Norwood et al. 3 reported the initial experience with palliative surgery followed by the first successful case of stage reconstruction surgery in 1983. 4 In 1978, an experimental laboratory program of neonatal HT was established at Loma Linda University, and in 1985, Bailey et al. 5 performed the first successful newborn HT.
With increasing experience with fetal echocardiography, prenatal identification of HLHS is increasing in frequency and prenatal counseling can be offered to parents. 6, 7 Kumar et al. 8 showed that prenatal diagnosis of HLHS improves the preoperative condition of neonates but may not improve preoperative mortality or early postoperative outcome. Despite the improvement in surgical management of HLHS, there is still controversy about the long-term outcome and ultimate benefits of active treatment. Physicians caring for newborn infants with HLHS continue to be faced with the ethical dilemma of recommending compassionate care or active treatment when the early clinical outcome is still evolving and long-term outcome is uncertain.
The purpose of the current study was (1) to review our 10-year experience in managing infants with HLHS in a geographic-based, province-wide population and (2) to establish a consistent approach in counseling families based on our current practice and based on review of recent medical literature.
METHODS
In this retrospective study, we reviewed the hospital records of all term and near-term infants admitted to the neonatal intensive care unit at the University of Alberta Hospital in Edmonton from January 1987 to July 1998 with the diagnosis of HLHS. Before 1987, compassionate care was the only management available in Edmonton, with a mortality of 100%. Since 1987, three different time periods were identified based on the different options available to parents.
For period 1 (1987 to 1993) , compassionate care, HT, and Norwood stage surgery (N) were offered. During period 2 (1994 to 1996) crossover from HT to N was also offered after 6 weeks on the waiting list for HT. In period 3 (1996 to 1998), compassionate care or N was offered. Before 1996, N or HT were not done in Edmonton and infants were transported by air for surgery. In 1996, a pediatric cardiovascular surgeon specializing in N was appointed to the University of Alberta Hospital.
After the diagnosis of HLHS was confirmed by echocardiography, a multidisciplinary team composed of a neonatologist, a pediatric cardiologist, a pediatric cardiovascular surgeon, and a social worker met with the family to discuss the different treatment options. The
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following data were collected from the medical record: gestational age, birth weight, gender, treatment options discussed with parents, parental choice, discharge status, and place and age at death. Statistical analysis was performed using a -squared test. A p value of Ͻ0.05 was considered significant.
RESULTS
The study group included 98 infants; 65 (67%) were male and 33 (33%) were female. Mean birth weight was 3310 gm (1820 to 4550 gm). The parents of 57 infants (58%) opted for compassionate care, and 41 (42%) opted for active treatment. Mean age of death for infants in the compassionate care group was 7 days (2 to 35 days). Of the 57 infants managed with compassionate care, 42 infants died in the University of Alberta Hospital neonatal intensive care unit, 5 infants were transferred back to die at the referring hospital, and 10 infants were discharged to die at home. Table 1 illustrates the initial management of infants by either compassionate care or active treatment during the three different time periods. There was a significant difference between periods 3 and 2 and between periods 3 and 1, with an increase in active treatment compared with compassionate care. Three infants initially enrolled in active treatment during period 1 were subsequently managed by compassionate care because of noncardiac abnormalities that excluded them from active treatment. No such infants were excluded during periods 2 and 3. Seven infants died while awaiting HT (six during period 1 and one during period 2). During period 2, two infants initially enrolled for HT had N after waiting 6 weeks for HT without finding a donor. Five infants during period 1 and two infants during period 2 had HT. All patients who had HT between 1987 to 1995 remain alive. During period 3, all infants who received active treatment underwent N. Table 2 illustrates the results of stage I N during the three time periods. All infants discharged from the hospital after stage I N subsequently underwent stage II and III N and survived during period 2. During period 3, only one infant died after discharge home after stage I N, and 10 of the 13 remaining infants underwent stage II N; all of these infants survived.
DISCUSSION
The management of infants with HLHS remains controversial. Although recent studies show improving results with surgical treatment of these infants, 9 -13 long-term cardiopulmonary and neurodevelopmental outcomes have not been established given the age of the oldest survivor. In a recent survey of 108 heads of academic departments of neonatology with residency training programs, active treatment was more widely recommended for treatment of HLHS than compassionate care. However, 78% of responders suggested the inclusion of compassionate care in their discussions with parents, suggesting that active treatment is still in transition from an experimental technology to becoming the standard of care.
14 With improvement in anesthesia, improvement in pre-and postoperative intensive care unit management, refinement of surgical techniques, and experience with surgery, the survival of infants with active treatment has improved dramatically over the last 5 to 10 years. Reported series show survival of up to 85% for stage I N and very low mortality (around 10%) for stages II and III. 15 In our study, during period 1, 5 of the 15 patients enrolled in active treatment received HT with excellent results (100% survival). There were significant practical problems associated with the process of HT. HT was not available in our institution, and the infant and family were required to travel to the United States transplant center (at Loma Linda) and live there for several months. The other major problem with HT was the shortage of donor availability for our patients. In the largest series of neonatal HT, 25% of infants died while on the waiting list. 16 This situation appears to be worsening, as a recent report demonstrated that waiting time for neonatal HT has increased significantly compared with earlier years. 17 With improving results in N and the lack of available donors, we began to offer a crossover from the HT waiting list to N after 6 weeks. With this change in approach, an increasing number of parents chose N over continued waiting for HT. During period 3, the local appointment of a cardiovascular surgeon experienced in N and an alteration in the pattern of provincial funding for referral outside Canada resulted in a dramatic decrease in referrals for HT. With active treatment results comparable with other centers now available in our own institution, we noted a dramatic increase in parents who chose active treatment.
Despite these excellent preliminary results, long-term results with either HT or N are lacking. Short-term results with HT have shown great improvement over the last 10 years. However, late rejection, graft coronary vasculopathy, and lymphoproliferative disease secondary to chronic use of immunotherapy remain a cause of concern for the future of these children. Survival with N continues to improve, but there is limited information about later cardiopulmonary and neurodevelopmental outcome. Rogers et al. 19 reported a 64% incidence of major developmental disabilities at 3 years in 11 survivors after N. In a recent report, Bove and Lloyd 20 described 70% survival at 5 years after N, with a 6% neurologic disability rate and a 10% occurrence of persistent cardiovascular complications in infants who had undergone all three stages of surgery. Kern et al. 21 reported on 14 infants with HLHS managed by N; these infants, who were Ͼ3 years of age, scored lower on average than matched family controls in different neuropsychologic tests.
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The best approach to the management of infants with HLHS remains controversial. Until recently, surgical treatment was widely regarded as experimental. 22 HLHS can act as a paradigm case for ethical decision-making in newborn infants because it combines the elements of a fatal disease, if not treated, with the uncertainty about long-term prognosis after an invasive and painful treatment. Before recent surgical options, infants with HLHS were given compassionate care at our institution. Parents and families were encouraged to be closely involved with the dying infants, and occasionally infants were discharged from the hospital or to a local hospital to die. The development of treatment options for HLHS has dramatically altered this clinical scenario. We consider that based on current results, HLHS can no longer be regarded as a uniformly fatal anomaly. Mothers with a prenatal ultrasound diagnosis of HLHS and infants with HLHS should be managed in centers with experience in active treatment. Prenatal and postnatal discussions with parents should include a balance of information and opinions about valid treatment options, including HT, N, and compassionate care.
Discussion of the outcome of active treatment should be realistic and based on current short-and long-term data. Uncertainty about the long-term outcome of active treatment should be shared honestly and openly with parents. As many infants with HLHS can be adequately stabilized in the neonatal intensive care unit for days or weeks with appropriate medical management, decisions about treatment should not be made in haste. In most cases, there should be plenty of time available to ensure that parents of neonates with HLHS are fully informed about the options available. Physicians caring for infants with HLHS must make sure that their own enthusiasm for life-saving surgical treatment does not interfere with the process of obtaining fully informed consent from parents by minimizing the considerable risks and uncertainty involved.
